We at CFIF often highlight the clear and present danger that drug price control schemes pose to American…
CFIF on Twitter CFIF on YouTube
New Lung Cancer Breakthrough Illustrates the Potential Peril of Drug Price Controls

We at CFIF often highlight the clear and present danger that drug price control schemes pose to American consumers, who benefit from our private pharmaceutical sector that leads the world - by far - in innovation.  A new lung cancer treatment breakthrough in the form of Amgen's Lumakras illustrates that interrelationship.

Simply put, Lumakras reduced the risk of progression by 34% compared to chemotherapy in patents with advanced lung cancer, which is particularly welcome considering lung cancer's especially low survival rate (18.6% over five years, and just 5% for advanced forms).  The breakthrough required years of research and enormous amounts of investment, however, which The Wall Street Journal notes makes Lumakras the type of innovation put at risk by new drug price controls…[more]

September 22, 2022 • 05:06 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's Courtroom Legal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts
CFIF Submits Formal Comment on NIST Proposed Rule Regarding Bayh-Dole Act of 1980 Print
By CFIF Staff
Monday, April 12 2021

Last week, the Center for Indvidiual Freedom (CFIF) submitted a formal Comment with the U.S. Commerce Department's National Institute of Standards and Technology (NIST) on its Proposed Rule regarding the Bayh-Dole Act of 1980, which granted universities, nonprofit organizations and small business the right to patent and license inventions funded partly by federal funding. 

The Economist magazine called the Bayh-Dole Act "Possibly the most inspired piece of legislation to be enacted in America over the past half century," and rightfully so.  It unleashed a tidal wave of hundreds of thousands of patents issued to American universities and research institutes since then. 

On that basis, CFIF supports the Proposed Rule to the extent that it advances the provisions and intent of Bayh-Dole, with the caveat that insertion of the terms "exclusively" and "of the contractor" in the Proposed Rule's text may open the door for advocates of drug price controls to suggest that business decisions of pharmaceutical innovators regarding the pricing of commercial goods and services arising from the practical application of inventions may serve as one basis for exercising march-in rights.  Neither the text nor the intent of the Bayh-Dole Act allow that, as namesake Senators Bayh and Dole themselves pointed out in a joint statement to The Washington Post

On that basis we urge that the Proposed Rule omit those terms.  We must ensure that Bayh-Dole's four-decade legacy of incredible success continues, without the looming threat that activists may attempt to use it to impose destructive drug price controls on American consumers.

Read CFIF's comment here (PDF).

Related Articles :
Quiz Question   
Which one of the following U.S. Presidents signed the executive order establishing the Federal Emergency Management Agency (FEMA)?
More Questions
Notable Quote   
 
"A coalition of 18 Republican states wrote a letter to Senate leadership Monday, announcing their opposition to Democrats' permitting reform legislation.The states' attorneys general, led by Louisiana Attorney General Jeff Landry, argued in the letter that the Energy Independence and Security Act -- which Sen. Joe Manchin, D-W.Va., unveiled last week -- would strip states of the authority to regulate…[more]
 
 
—Thomas Catenacci and Peter Hasson, FOX Business
— Thomas Catenacci and Peter Hasson, FOX Business
 
Liberty Poll   

Choosing from the list below, what issue is currently most important to you heading into the mid-term elections?